The use of targeted therapies have led to an increase in survival of lung cancer patients with certain genetic alterations such as epidermal growth factor receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements [5–7]. This evidence concerns the gene EGFR and lung carcinoma.